What is Shandong Sito Bio-technology Co Median PS Value?
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Shandong Sito Bio-technology Co's Median PS Value or its related term are showing as below:
SZSE:300583's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.665 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Shandong Sito Bio-technology Co Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Shandong Sito Bio-technology Co Median PS Value Chart
Competitive Comparison of Shandong Sito Bio-technology Co's Median PS Value
For the Biotechnology subindustry, Shandong Sito Bio-technology Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Sito Bio-technology Co's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shandong Sito Bio-technology Co's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Shandong Sito Bio-technology Co's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Shandong Sito Bio-technology Co's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥6.124.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Sito Bio-technology Co (SZSE:300583) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Shandong Sito Bio-technology Co's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
24.77
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Sito Bio-technology Co Median PS Value Related Terms
Thank you for viewing the detailed overview of Shandong Sito Bio-technology Co's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Shandong Sito Bio-technology Co Business Description
Shandong Sito Bio-technology Co Ltd is a biotechnology company. It uses genetic engineering technology and microbial transformation technology to develop and produce steroid drug raw materials, specialty respiratory raw materials and finished preparations, and other drug intermediaries. The company operates in the following business segments; intermediates, high-end specialty respiratory APIs, and preparations. Its product offerings include androstenedione (AD), 9-hydroxy androstenedione (90H-AD), 17a-hydroxyprogesterone derivatives (A ring), and bi-decanoic acid (BA), and others. In addition, the company holds patents for various APIs and other intermediaries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:300583 has been successfully added to your 